Objective-To study
Abstract Objective-To study the possible association of purine enzyme activities with response to azathioprine (AZA) treatment in rheumatoid arthritis (RA) and their correlation with parameters of disease activity. Patients and methods--Lymphocyte activities of hypoxanthine-guanine phosphoribosyl-transferase (HGPRT), adenine phosphoribosyltransferase (APRT), purine nucleoside phosphorylase (PNP) and 5'-nucleotidase (5NT), and erythrocyte activities of thiopurine methyltransferase (TPMT) were measured in 14 healthy controls and 36 patients with RA. Eight patients had not previously been treated with AZA. Response to AZA therapy in 28 patients, determined in a prospective trial, was considered good in nine (group 1), insufficient in seven (group 2). In 12 patients AZA was withdrawn because of adverse reactions (group 3). Disease activity parameters were obtained simultaneously with purine enzyme measurements. Purine enzyme levels in the different groups were compared. Results-Levels of SNT activity were significantly lower in patients with RA than in healthy controls. PNP activity was higher in patients with RA not using prednisone compared with those who did and healthy controls. No clear correlation between purine enzyme levels and disease activity parameters was found. 5NT activities were significantly higher in group one than in group three (p = 0-012; a = 0.017), and almost significantly higher than in group two (p = 0 03; a = 0.017). After conversion to 6-mercaptopurine (6MP) the metabolism of azathioprine (AZA) parallels the endogenous purine pathways. Deficiencies of purine enzymes may reduce efficacy or increase toxicity of AZA. To our knowledge, the relation between purine enzyme levels and response to AZA therapy in patients with RA has not been systematically studied so far. The present study was undertaken to investigate purine enzyme activities in patients with RA and their association with response to AZA therapy.
Patients and methods

PATIENTS
Thirty six patients with classic or definite RA4 were studied. Eight patients had not previously been exposed to AZA. The other 28 patients had been treated with AZA during a doubleblind prospective trial of AZA and methotrexate,5 and could be assigned to three groups according to their response to AZA therapy. Erythrocyte sedimentation rate (ESR, Westergren), whole blood count and liver and kidney function tests were obtained simultaneously with the measurement of purine enzyme activities. Lymphocyte activities of 5'-nucleotidase (5NT), purine nucleoside phosphorylase (PNP), hypoxanthine-guanine phosphoribosyltransferase (HGPRT) and adenosine phosphoribosyl-transferase (APRT) and erythrocyte activities of thiopurine methyltransferase (TPMT) were measured using micro-enzymatic radiochemical assays as described previously.8 9 The analyst was 'blind' for the clinical data at the time purine enzymes were measured. All assays were done in quadruplicate.
STATISTICAL ANALYSIS
Student's t test or Wilcoxon's two-sample test was used to compare purine enzyme activities between patients and healthy controls, between sexes and between patients with or without prednisone. Correlations between purine enzymes and disease activity parameters were assessed according to Pearson or Spearman.
Levels of purine enzymes in the three groups of patients were compared by one-way analyses of variance. In case of non-normality the Kruskall-Wallis test was applied, followed by pairwise Wilcoxon's tests, using the Bonferroni principle with ad3 as the level of significance.
Tests were two-sided with ot = 0-05. Patients with deficiencies of purine enzymes known to influence the response to AZA treatment, such as HGPRT and TPMT deficiency, were excluded from this part of the analysis. had to be withdrawn in the meantime because RA had relapsed. Adverse reactions leading to AZA-withdrawal included GI discomfort (n = 6), elevated transaminases (n = 4), drugfever (n = 3), pancytopenia (n = 1), and mild leucopenia (n = 1).
PURINE ENZYME LEVELS proportion of patients using prednisone. The overall hypothesis of equal levels of 5NT activity in the three response groups had to be rejected (p = 002) ( Our obervations in the three groups of patients with different responses to AZA therapy are of special interest. Generally, cytotoxic thionucleotides are held responsible for both the favourable and toxic effects of AZA, suggesting that purine enzymes determine the effects of AZA by directly influencing the levels of cytotoxic metabolites. If this were to be the underlying mechanism, activities of catabolic enzymes, such as 5NT, would be expected to be low both in good responders and in patients experiencing adverse reactions, and higher in those who lack efficacy. Contrary to this relatively simple model, we found higher lymphocyte activities of 5NT in good responders than in both other groups. Perhaps, a presently not well understood more delicate balance between purine enzyme activities and products of (thio-) purine metabolism determining the final outcome of AZA treatment in RA must be considered. Prospective studies are needed to confirm our findings and will help in a better understanding of the mode of action of AZA in RA.
In conclusion, this study indicates that purine enzyme activities in patients with RA differ from healthy controls, may be associated with the outcome of AZA treatment, and seem not to be associated with disease activity.
The aetiopathogenetic and clinical implications of these findings need to be clarified. We believe that the possible identification of a factor predicting the response to AZA treatment in patients with RA merits the efforts of prospective studies.
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